Welcome to our dedicated page for Exelixis news (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis stock.
Exelixis Inc. reports developments from its oncology business, including commercial performance for the cabozantinib franchise and clinical and regulatory updates across cancer programs. The company discovers, develops and commercializes cancer medicines, with CABOMETYX® (cabozantinib) as its flagship commercial product and COMETRIQ® also part of its cabozantinib portfolio.
Recurring updates include quarterly financial results, product revenue trends, financial guidance, pipeline milestones and investor conference presentations. Exelixis also discusses zanzalintinib, an investigational oral kinase inhibitor, and a broader pipeline of small molecules and biotherapeutics targeting additional tumor types and indications.
Exelixis (Nasdaq: EXEL) reported second quarter 2026 total revenues of $628.7 million, up from $568.3 million a year earlier, driven by U.S. cabozantinib franchise net product revenues of $573.0 million and collaboration revenues of $55.7 million. GAAP diluted EPS was $0.82 versus $0.65, and non-GAAP diluted EPS was $0.91 versus $0.75.
Research and development expenses rose to $212.0 million and SG&A to $147.6 million, while GAAP net income increased to $212.1 million. For 2026, Exelixis updated guidance to total revenues of $2.50–$2.55 billion and net product revenues of $2.30–$2.35 billion, with reduced R&D expense guidance of $825–$875 million.
According to the company, cabozantinib collaboration royalties totaled $53.2 million, and the FDA is reviewing its NDA for zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer with a PDUFA target date of December 3, 2026. Multiple phase 2 and 3 trials of zanzalintinib across tumor types are ongoing or being initiated.
Exelixis (Nasdaq: EXEL) will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after the market close. Management will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to review results and provide a business update.
Exelixis (Nasdaq: EXEL) reported final overall survival (OS) results in the non-liver metastases (NLM) subgroup of the phase 3 STELLAR-303 trial of zanzalintinib plus atezolizumab versus regorafenib in previously treated metastatic colorectal cancer.
The NLM subgroup showed a non-statistically significant OS trend favoring the combination (HR 0.83; 95% CI 0.66–1.05; P=0.1185), with median OS of 15.9 vs 12.7 months. Safety was consistent with the overall population, with no new safety signals. STELLAR-303 previously met its other dual primary endpoint, showing a statistically significant OS benefit in the full ITT population. The FDA has accepted the NDA for this regimen, with a PDUFA target action date of December 3, 2026.
Exelixis (Nasdaq: EXEL) reported subgroup results from the phase 3 CABINET trial of CABOMETYX (cabozantinib) in previously treated advanced neuroendocrine tumors (NET) at ASCO 2026.
Cabozantinib reduced the risk of disease progression or death by 74% in non-functional and 60% in functional NET versus placebo and improved median progression-free survival across subgroups, with a safety profile consistent with prior experience.
Exelixis (Nasdaq: EXEL) will webcast fireside chats from two June 2026 investor conferences. Management will present at the Jefferies Global Healthcare Conference on June 3 at 11:05 a.m. ET in New York and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 at 10:40 a.m. ET in Miami.
Live webcasts and 30-day replays will be available via the Event Calendar on the Investors & News section of www.exelixis.com.
Exelixis (Nasdaq: EXEL) will present new data on CABOMETYX (cabozantinib) and investigational kinase inhibitor zanzalintinib at the ASCO 2026 Annual Meeting, held May 29–June 2 in Chicago.
Presentations span phase 2 and phase 3 trials across kidney cancer, neuroendocrine tumors, colorectal cancer, sarcoma, thyroid, urothelial and pediatric solid tumors.
Exelixis (Nasdaq: EXEL) announced a clinical development collaboration with Merck for the planned phase 3 pivotal trial STELLAR-316 in resected stage II/III colorectal cancer.
Exelixis will sponsor the trial, Merck will supply KEYTRUDA QLEX, and Natera’s Signatera assay will identify MRD+ patients. Trial initiation is expected in mid-2026.
Exelixis (NASDAQ: EXEL) will webcast management fireside chats at four investor conferences in May 2026. Presentations are scheduled for May 12 (BofA Health Care, 1:00 p.m. ET), May 19 (RBC, 9:00 a.m. ET), May 20 (Stifel virtual, 1:30 p.m. ET) and May 27 (Bernstein, 3:30 p.m. ET).
Webcasts and replays will be available at www.exelixis.com on the Event Calendar under Investors & News for at least 30 days.
Exelixis (Nasdaq: EXEL) reported Q1 2026 revenues of $610.8M, including cabozantinib U.S. net product revenues of $555.0M. GAAP diluted EPS was $0.79 and non-GAAP diluted EPS was $0.87. The company announced a new $750M stock repurchase program through end of 2027 and an FDA PDUFA date of Dec 3, 2026 for zanzalintinib.
Guidance for 2026 is maintained with total revenue guidance of $2.525B–$2.625B and R&D guidance of $875M–$925M.
Exelixis (Nasdaq: EXEL) will release its first quarter 2026 financial results on Tuesday, May 5, 2026 after the market close. Management will host a conference call and live webcast the same day at 5:00 p.m. ET / 2:00 p.m. PT.
Access is available via the company website Event Calendar under Investors & News; a replay will be archived for one year.